Superior Planning, LLC’s Mineralys Therapeutics MLYS Stock Holding History

Superior Planning, LLC’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$779	Buy	+31	New	+$844	﹤0.01%	1808

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Superior Planning, LLC's MLYS Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Mineralys Therapeutics (MLYS) in Q3 2026: 31 shares worth $779. The stake represents ﹤0.01% of the portfolio and ranks #1808 among its holdings.

111 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

Superior Planning, LLC held 31 shares of Mineralys Therapeutics worth $779 as of Q3 2026.
Mineralys Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Mineralys Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1808 holding.
111 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.